Accesswire
17 Jun 2026, 06:00 UTC · 3h ago
Genflow Biosciences PLC - Company to present at Animal Longevity Summit 2026
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Accesswire
17 Jun 2026, 06:00 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Genflow Biosciences will present data from its SLAB clinical study on SIRT6 gene therapy at the Animal Longevity Summit in October 2026. — The presentation of a 'comprehensive dataset' from a clinical study is a primary catalyst for biotech valuations as it validates or invalidates the core technology.
+0.40The SLAB study, evaluating SIRT6 gene therapy in aged beagles, concluded in June 2026. — The completion of the study means final results are now available, moving the company closer to potential human applications or commercialization.
+0.20Genflow is developing GF-1002, a SIRT6-centenarian gene therapy, with applications for both veterinary health and human diseases such as MASH. — Expanding the target market from companion animals to chronic human liver disease increases the total addressable market (TAM) for the lead compound.
+0.10Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company has been invited to present comprehensive clinical study data at a major industry summit, signaling progress in its longevity research.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
4h ago
